Market Overview

Sanofi Announces Data Show Lyxumia Added to Basal Insulin Lowered Blood Sugar in Patients with Type 2 Diabetes

Sanofi (NYSE: SNY) announced today new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia® (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). These findings are consistent with the efficacy profile of Lyxumia, which shows a clinical and statistically significant reduction in HbA1c across different patient populations.

(Logo:  http://photos.prnewswire.com/prnh/20130924/NY84445LOGO)

The results also showed that reductions in body weight with Lyxumia, when added to basal insulin, were greatest in this group. The GetGoal-L sub-analysis was shared during an oral presentation at the 49th Annual Meeting of the European Association for the Study of Diabetes in Barcelona.

"The study showed that Lyxumia is an effective post-prandial glucose lowering option that improves HbA1c levels when added to basal insulin," said Professor Josep Vidal, Endocrinology and Nutrition, University of Barcelona. "We analyzed data from patients who were not at their target HbA1c level, despite controlled fasting plasma glucose, and we found that a treatment regimen that targets post-prandial glucose, as well as fasting plasma glucose, could be an effective choice

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional